Themis Medicare (THEMISMED) Stock Overview
Manufactures and sells pharmaceutical products in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
THEMISMED Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Themis Medicare Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹100.28 |
| 52 Week High | ₹317.00 |
| 52 Week Low | ₹99.04 |
| Beta | -0.22 |
| 1 Month Change | -9.98% |
| 3 Month Change | -27.86% |
| 1 Year Change | -61.81% |
| 3 Year Change | 21.63% |
| 5 Year Change | 191.81% |
| Change since IPO | 681.61% |
Recent News & Updates
Recent updates
Earnings Not Telling The Story For Themis Medicare Limited (NSE:THEMISMED) After Shares Rise 27%
May 20
More Unpleasant Surprises Could Be In Store For Themis Medicare Limited's (NSE:THEMISMED) Shares After Tumbling 27%
Mar 07Does Themis Medicare (NSE:THEMISMED) Have A Healthy Balance Sheet?
Feb 13Investor Optimism Abounds Themis Medicare Limited (NSE:THEMISMED) But Growth Is Lacking
Jan 21What Themis Medicare Limited's (NSE:THEMISMED) 42% Share Price Gain Is Not Telling You
Dec 27Themis Medicare (NSE:THEMISMED) Takes On Some Risk With Its Use Of Debt
Dec 01Themis Medicare (NSE:THEMISMED) Has Affirmed Its Dividend Of ₹5.00
Aug 18Themis Medicare's (NSE:THEMISMED) Dividend Will Be ₹5.00
Aug 04Themis Medicare's (NSE:THEMISMED) Dividend Will Be ₹5.00
Jul 18We Think Themis Medicare (NSE:THEMISMED) Is Taking Some Risk With Its Debt
Jul 08Themis Medicare (NSE:THEMISMED) Is Due To Pay A Dividend Of ₹5.00
May 18Themis Medicare (NSE:THEMISMED) Seems To Use Debt Quite Sensibly
Dec 21Themis Medicare (NSE:THEMISMED) Has Announced That It Will Be Increasing Its Dividend To ₹5.00
Aug 28Themis Medicare (NSE:THEMISMED) Is Increasing Its Dividend To ₹5.00
Aug 08Themis Medicare's (NSE:THEMISMED) Upcoming Dividend Will Be Larger Than Last Year's
Jul 21Themis Medicare's (NSE:THEMISMED) Upcoming Dividend Will Be Larger Than Last Year's
May 27Is Now The Time To Put Themis Medicare (NSE:THEMISMED) On Your Watchlist?
May 12Calculating The Fair Value Of Themis Medicare Limited (NSE:THEMISMED)
Nov 09Is Now The Time To Put Themis Medicare (NSE:THEMISMED) On Your Watchlist?
Oct 26Increases to Themis Medicare Limited's (NSE:THEMISMED) CEO Compensation Might Cool off for now
Sep 11Themis Medicare (NSE:THEMISMED) Is Increasing Its Dividend To ₹4.30
Aug 16Shareholder Returns
| THEMISMED | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -5.0% | -1.2% | -1.2% |
| 1Y | -61.8% | -4.6% | -7.1% |
Return vs Industry: THEMISMED underperformed the Indian Pharmaceuticals industry which returned -4.6% over the past year.
Return vs Market: THEMISMED underperformed the Indian Market which returned -7.1% over the past year.
Price Volatility
| THEMISMED volatility | |
|---|---|
| THEMISMED Average Weekly Movement | 5.7% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in IN Market | 8.0% |
| 10% least volatile stocks in IN Market | 3.3% |
Stable Share Price: THEMISMED has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: THEMISMED's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1952 | 1,702 | Sachin Patel | www.themismedicare.com |
Themis Medicare Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients (APIs) and formulations used in various therapeutic areas, including anti-tuberculosis, analgesic and anti-inflammatory, analgesic and antispasmodic, analgesics, anesthesia, antacid-antiflatulent, anti-fungal, antibiotic, anti-diabetic, anti-emetic, anti-hypertensive, anti-allergic and anti-inflammatory, anti-allergic and appetite stimulant, anticoagulant, antifibrolytic, antimalarial, anti-muscarinic, antioxidant, calcium, cardiovascular, corticosteroid, electrolytes, expectorant, hematinic, hemostatic agent, hemostatic agent with anesthetic, hormones, immunomodulator with anti-viral, muscle relaxant, narcotic analgesic, neuropathy, nutraceuticals, PPI, probiotic, reversal for muscle relaxant, sedatives, skeletal muscle relaxant, skeletal muscle relaxant and analgesic and anti-inflammatory, vasodilator, vasopressors, and vitamins. The company was formerly known as Themis Chemicals and changed its name to Themis Medicare Limited in 2001.
Themis Medicare Limited Fundamentals Summary
| THEMISMED fundamental statistics | |
|---|---|
| Market cap | ₹9.23b |
| Earnings (TTM) | -₹90.71m |
| Revenue (TTM) | ₹3.80b |
Is THEMISMED overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| THEMISMED income statement (TTM) | |
|---|---|
| Revenue | ₹3.80b |
| Cost of Revenue | ₹1.43b |
| Gross Profit | ₹2.37b |
| Other Expenses | ₹2.46b |
| Earnings | -₹90.71m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 14, 2025
| Earnings per share (EPS) | -0.99 |
| Gross Margin | 62.35% |
| Net Profit Margin | -2.39% |
| Debt/Equity Ratio | 20.6% |
How did THEMISMED perform over the long term?
See historical performance and comparisonDividends
Does THEMISMED pay a reliable dividends?
See THEMISMED dividend history and benchmarks| Themis Medicare dividend dates | |
|---|---|
| Ex Dividend Date | Sep 04 2025 |
| Dividend Pay Date | Oct 12 2025 |
| Days until Ex dividend | 7 days |
| Days until Dividend pay date | 45 days |
Does THEMISMED pay a reliable dividends?
See THEMISMED dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/27 19:35 |
| End of Day Share Price | 2025/08/26 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Themis Medicare Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anil Burra | FirstCall Research |